Osteoblast proliferation and maturation by bisphosphonates

被引:325
作者
Im, GI [1 ]
Qureshi, SA [1 ]
Kenney, J [1 ]
Rubash, HE [1 ]
Shanbhag, AS [1 ]
机构
[1] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Dept Orthopaed Surg,Biomat Lab, Boston, MA 02114 USA
关键词
alendronate; risedronate; human trabecular bone cells; BMP-2; total joint replacements;
D O I
10.1016/j.biomaterials.2003.11.024
中图分类号
R318 [生物医学工程];
学科分类号
0831 ;
摘要
Aseptic loosening and osteolysis are currently the most common causes of failure of total joint replacements. Osteolysis is initiated by a macrophage response to wear debris, resulting in localized, osteoclastic peri-implant bone loss. We have previously inhibited osteoclast-mediated bone resorption in a canine total hip arthroplasty model using oral bisphosphonate therapy. Based on serendipitous observations from our canine study, we hypothesized that bisphosphonates have an anabolic effect on osteoblasts, in a manner distinct from their inhibitory effect on osteoclastic bone resorption. We studied the anabolic effects of two FDA-approved bisphosphonates (alendronate and risedronate) on two in vitro models: a primary human trabecular bone cell culture and the MG-63 osteoblast-like cell line. Following treatment with bisphosphonates at varying concentrations and time periods. cells were assayed for proliferation effects and results were quantified using the methods of direct cell count, and the colorimetric MTT (3-dimethylthiazol-2,5-diphenyltetrazolium bromide) assay at 24, 48, and 72 It. The effect of bisphosphonates on the maturation of osteoblasts were tested with alkaline phosphatase bioassay and reverse transcription-polymerase chain reaction for markers of osteoblast differentiation. Results from both the primary human trabecular bone cell culture and the MG-63 osteoblast-like cell line showed that both bisphosphonates significantly increased the cell number over controls, attaining peak levels at a concentration of 10(-8) m. Alkaline phosphatase activity was also increased, representing earlier commitment of osteoprogenitor cells towards the osteoblastic phenotype. Bisphosphonates also enhanced gene expression of BMP-2, Type I collagen and osteocalcin. In summary, bisphosphonates, aside from their role as inhibitors of osteoclastic bone resorption, are promoters of osteoblast proliferation and maturation. (C) 2003 Elsevier Ltd. All rights reserved.
引用
收藏
页码:4105 / 4115
页数:11
相关论文
共 73 条
  • [1] The effects of particulate polyethylene at a weight-bearing bone-implant interface - A study in rats
    Allen, M
    Brett, F
    Millett, P
    Rushton, N
    [J]. JOURNAL OF BONE AND JOINT SURGERY-BRITISH VOLUME, 1996, 78B (01): : 32 - 37
  • [2] The effects of diamond-like carbon coatings on macrophages, fibroblasts and osteoblast-like cells in vitro
    Allen, M.
    Law, F.
    Rushton, N.
    [J]. Clinical Materials, 1994, 17 (01): : 1 - 10
  • [3] Fluid pressure may cause periprosthetic osteolysis - Particles are not the only thing
    Aspenberg, P
    van der Vis, H
    [J]. ACTA ORTHOPAEDICA SCANDINAVICA, 1998, 69 (01): : 1 - 4
  • [4] Åström E, 1998, ACTA PAEDIATR, V87, P64
  • [5] Balena R, 1996, J PHARMACOL EXP THER, V276, P277
  • [6] Intravenous pamidronate treatment in osteogenesis imperfecta
    Bembi, B
    Parma, A
    Bottega, M
    Ceschel, S
    Zanatta, M
    Martini, C
    Ciana, G
    [J]. JOURNAL OF PEDIATRICS, 1997, 131 (04) : 622 - 625
  • [7] Randomised trial of effect of alendronate on risk of fracture in women with existing vertebral fractures
    Black, DM
    Cummings, SR
    Karpf, DB
    Cauley, JA
    Thompson, DE
    Nevitt, MC
    Bauer, DC
    Genant, HK
    Haskell, WL
    Marcus, R
    Ott, SM
    Torner, JC
    Quandt, SA
    Reiss, TF
    Ensrud, KE
    [J]. LANCET, 1996, 348 (9041) : 1535 - 1541
  • [8] BOONEKAMP PM, 1986, BONE MINER, V1, P27
  • [9] Histomorphometric assessment of the long-term effects of alendronate on bone quality and remodeling in patients with osteoporosis
    Chavassieux, PM
    Arlot, ME
    Reda, C
    Wei, L
    Yates, AJ
    Meunier, PJ
    [J]. JOURNAL OF CLINICAL INVESTIGATION, 1997, 100 (06) : 1475 - 1480
  • [10] EGGELMEIJER F, 1994, J RHEUMATOL, V21, P2016